A Tale of Two Tracers: Glucose Metabolism and Amyloid Positron Emission Tomography Imaging in Alzheimer's Disease
A Tale of Two Tracers: Glucose Metabolism and Amyloid Positron Emission Tomography Imaging in Alzheimer's Disease
复制标题
DOI：
10.3233/978-1-60750-793-2-219
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
de Leon, Mony J.
中科院分区：
文献类型：
--
作者：
Mosconi, Lisa;Berti, Valentina;de Leon, Mony J.
阿尔茨海默病（AD）预防疗法的发展将大大受益于对临床症状发作前发生的细微脑变化敏感的生物标志物，此时功能保留的潜力最大。体内脑成像是一种很有前途的工具，通过可视化的异常，脑结构，功能和组织病理学的早期检测AD。目前，使用淀粉样蛋白-β（A β）示踪剂和2-[F-18]氟-2-脱氧-D-葡萄糖（FDG）的正电子发射断层扫描（PET）成像主要用于AD的早期和鉴别诊断。A β PET示踪剂与脑中的A β斑块结合，并提供AD病理学的体内估计。FDG-PET用于测量葡萄糖代谢，这是大脑活动的标志。本文综述了AD患者以及有AD风险的非痴呆个体的脑A β和FDG-PET研究。然后，我们讨论了将磁共振敏感的FDG-PET测量与病理特异性A β-PET相结合以提高AD的早期检测的潜力。
The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit from biomarkers that are sensitive to subtle brain changes occurring prior to the onset of clinical symptoms, when the potential for preservation of function is at the greatest. In vivo brain imaging is a promising tool for the early detection of AD through visualization of abnormalities in brain structure, function and histopathology. Currently, Positron Emission Tomography ( PET) imaging with amyloid-beta ( A beta) tracers and 2-[F-18] fluoro-2-Deoxy-D-glucose ( FDG) is largely utilized in the early and differential diagnosis of AD. A beta PET tracers bind to A beta plaques in brain, and provide an in vivo estimate of AD pathology. FDG-PET is used to measure glucose metabolism, a marker of brain activity. This paper reviews brain A beta- and FDG-PET studies in AD patients as well as in non-demented individuals at risk for AD. We then discuss the potential of combining symptoms-sensitive FDG-PET measures with pathology-specific A beta-PET to improve the early detection of AD.